Forecast

There is no analyst data available for this company.

News Go to news feed

ENvue Medical relocates NanoVibronix production entirely to the United States

ENvue Medical has completed the relocation of NanoVibronix manufacturing from Israel to the United States and now produces the entire product line in the U.S. Research and development activities remain consolidated in Tel Aviv. The company expects the consolidation to deliver lower operating costs, improved operational efficiency and optimized supply-chain management; affected devices include PainShield and UroShield. » More on de.investing.com
NanoVibronix reports quarterly loss per share of $6.88, revenue falls 36%

NanoVibronix released results for the quarter ended March 31, 2026: earnings per share were -$6.88 compared with -39,800 USD in the prior year. Revenue fell 36.27% to $0.7 million (prior year: $1.0 million). » More on finanzen.net
NanoVibronix rebrands as ENvue Medical and trades under FEED

NanoVibronix has changed its corporate name to ENvue Medical and is now listed on the Nasdaq Capital Market under the ticker symbol FEED. The company is strategically focused on its electromagnetic ENvue probe placement platform, which holds FDA 510(k) clearance for adults and is in use at 38 U.S. hospitals. NanoVibronix has a market capitalization of about $4.37 million, a current ratio of 0.86 and saw its share price fall 94% over the past year; it recently raised roughly $2 million in a registered direct offering and filed a new U.S. patent. Existing shareholders do not need to take any action, and the CUSIP number of the common stock remains unchanged. » More on de.investing.com

Financials

In the last quarter, NANOVIBRONIX DL-,001 had revenue of €209.41K and net profit of -€4.3M

(EUR)	Jun 2026	YoY
Revenue	209.41K	50.03%
Gross profit	-233.07K	684.89%
Net profit	-4.3M	3,145.89%
EBITDA	-4.8M	66.22%

Fundamentals

Metric	Value
Market capitalization	€1.31M
Number of shares	796.92K
52-week high/low	€140.29 - €0.91
Dividends	No
Beta	2.06
P/E ratio	0.00
PEG ratio	0.00
P/B ratio	0.07
P/S ratio	1.66

Company profile

NanoVibronix, Inc. konzentriert sich über seine Tochtergesellschaft NanoVibronix Ltd. auf die Herstellung und den Verkauf von nicht-invasiven, biologische Reaktionen aktivierenden Geräten, die auf die Prävention von Biofilm, Wundheilung und Schmerztherapie abzielen. Zu den wichtigsten Produkten gehören UroShield, ein ultraschallbasiertes Produkt zur Verhinderung der bakteriellen Besiedlung und des Biofilms in Harnkathetern, zur Verbesserung der Wirksamkeit von Antibiotika und zur Verringerung von Schmerzen und Beschwerden im Zusammenhang mit der Verwendung von Harnkathetern; PainShield, eine pflasterbasierte therapeutische Ultraschalltechnologie zur Behandlung von Schmerzen, Muskelkrämpfen und Gelenkkontrakturen; und WoundShield, ein pflasterbasiertes therapeutisches Ultraschallgerät, das die Geweberegeneration und Wundheilung fördert. Das Unternehmen vertreibt seine Produkte direkt an Patienten sowie über Vertriebsvereinbarungen in den Vereinigten Staaten, Israel, Europa, Indien und international. NanoVibronix, Inc. wurde im Jahr 2003 gegründet und hat seinen Sitz in Elmsford, New York.

Name	NANOVIBRONIX DL-,001
CEO	Doron Robert Besser
Headquarters	Elmsford, ny USA
Website	nanovibronix.com
Sector	Industrials
Industry	Commercial Services & Supplies
IPO	05/28/2015
Employees	31